Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2026
Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.
Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase 3 randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of pf-04965842 monotherapy in subjects aged 12 years and older, with moderate to severe atopic dermatitis
A phase 3 multi-center, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis
A phase 3 randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of pf-04965842 monotherapy in subjects aged 12 years and older, with moderate to severe atopic dermatitis
A phase 3 randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center study investigating the efficacy and safety of pf-04965842 and dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis
A phase 3, randomized, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of pf-04965842 co-administered with background medicated topical therapy in adolescent participants 12 to <18 years of age with moderate-to-severe atopic dermatitis
A phase 2a, randomized, double-blind, placebo-controlled, parallel group, multi-center study to investigate the mechanism of action of abrocitinib monotherapy in adult participants with moderate-to-severe atopic dermatitis
A phase 3b randomized, double-blind, double-dummy, active controlled multi-center study assessing the efficacy and safety of abrocitinib compared with dupilumab in adult participants on background topical therapy with moderate to severe atopic dermatitis
Who cites it
5 citing papers in PubMed.
- Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials.Dermatology and therapy · 2026Article
- Two-year abrocitinib in atopic dermatitis: Are we reaching the new targets?Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis.Dermatology and therapy · 2026Article
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAbrocitinib treatment previously showed clinically meaningful improvements in skin signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) up to 48 weeks, with a manageable safety profile.
objectiveTo further evaluate long-term efficacy and patient-reported outcomes (PROs) with abrocitinib in patients with moderate-to-severe AD up to 112 weeks of treatment.
methodsJADE EXTEND (NCT03422822), an ongoing, phase 3, long-term extension study of previous abrocitinib trials, includes patients from qualifying trials MOA (NCT03915496), MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), TEEN (NCT03796676) and DARE (NCT04345367). Efficacy assessments include the proportion of patients achieving IGA score of 0 or 1 (IGA 0/1); absolute Eczema Area and Severity Index ≤7 (EASI ≤ 7), ≥75%/≥90%/100% improvement in EASI (EASI-75/-90/-100); ≥4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4); PP-NRS score of 0 or 1 (PP-NRS 0/1); EASI-90 + PP-NRS 0/1. PROs include Dermatology Life Quality Index score of 0 or 1 (DLQI 0/1), Children's Dermatology Life Quality Index score of 0 or 1 (CDLQI 0/1), Patient Global Assessment score of 0 or 1 (PtGA 0/1), and ≥4-point improvement in Patient-Oriented Eczema Measure (POEM ≥ 4). Data cut-off: 5 September 2022.
resultsAt data cut-off, 403 (42%) and 425 (56%) patients received abrocitinib 200 mg and abrocitinib 100 mg, respectively, for ≥112 weeks. Week 112 efficacy responses were IGA 0/1 57% and 52%; EASI ≤7 81% and 77%; EASI-75 84% and 78%; EASI-90 61% and 54%; EASI-100 26% and 21%; PP-NRS4 70% and 58%; PP-NRS 0/1 43% and 33%; EASI-90 + PP-NRS 0/1 37% and 30%. Week 112 PROs were DLQI 0/1 43% and 41%; CDLQI 0/1 59% and 39%; PtGA 0/1 75% and 72%; POEM ≥4 88% and 81%.
conclusionsAbrocitinib treatment resulted in clinically meaningful outcomes and improvements in PROs, including high-threshold endpoints, in substantial proportions of patients with moderate-to-severe AD up to 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.